Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review

Karthik Nagaraja Rao; Gregory W. Randolph; Fernando Lopez; Mark Zafereo; Andrés Coca-Pelaz; Cesare Piazza; Prajwal Dange; Juan Pablo Rodrigo; Göran Stenman; Bart de Keizer; Iain Nixon; Shriyash Sinha; Sophie Leboulleux; Antti A. Mäkitie; Abbas Agaimy; Lester Thompson; Alfio Ferlito

doi:10.1007/s12020-024-03737-z

Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review

Karthik Nagaraja Rao, Gregory W. Randolph, Fernando Lopez, Mark Zafereo, Andrés Coca-Pelaz, Cesare Piazza, Prajwal Dange, Juan Pablo Rodrigo, Göran Stenman, Bart de Keizer, Iain Nixon, Shriyash Sinha, Sophie Leboulleux, Antti A. Mäkitie, Abbas Agaimy, Lester Thompson, Alfio Ferlito

Head & Neck Surgery

Research output: Contribution to journal › Review article › peer-review

Abstract

The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.

Original language	English (US)
Journal	Endocrine
DOIs	https://doi.org/10.1007/s12020-024-03737-z
State	Accepted/In press - 2024

Keywords

Artificial intelligence
Bethesda system
Molecular testing
Risk assessment
Thyroid neoplasms

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/s12020-024-03737-z

Cite this

Rao, K. N., Randolph, G. W., Lopez, F., Zafereo, M., Coca-Pelaz, A., Piazza, C., Dange, P., Rodrigo, J. P., Stenman, G., de Keizer, B., Nixon, I., Sinha, S., Leboulleux, S., Mäkitie, A. A., Agaimy, A., Thompson, L., & Ferlito, A. (Accepted/In press). Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review. Endocrine. https://doi.org/10.1007/s12020-024-03737-z

@article{1ce3dabf16fa42cf87f8f2ee66605e7e,

title = "Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review",

abstract = "The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma{\textregistered} GEC, Afirma{\textregistered} GSC, ThyroSeq{\textregistered} V3, RosettaGX{\textregistered}, ThyGeNEXT{\textregistered}/ThyraMIR{\textregistered}, ThyroidPRINT{\textregistered}) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.",

keywords = "Artificial intelligence, Bethesda system, Molecular testing, Risk assessment, Thyroid neoplasms",

author = "Rao, {Karthik Nagaraja} and Randolph, {Gregory W.} and Fernando Lopez and Mark Zafereo and Andr{\'e}s Coca-Pelaz and Cesare Piazza and Prajwal Dange and Rodrigo, {Juan Pablo} and G{\"o}ran Stenman and {de Keizer}, Bart and Iain Nixon and Shriyash Sinha and Sophie Leboulleux and M{\"a}kitie, {Antti A.} and Abbas Agaimy and Lester Thompson and Alfio Ferlito",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

doi = "10.1007/s12020-024-03737-z",

language = "English (US)",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

}

TY - JOUR

T1 - Assessment of the risk of malignancy in Bethesda III thyroid nodules

T2 - a comprehensive review

AU - Rao, Karthik Nagaraja

AU - Randolph, Gregory W.

AU - Lopez, Fernando

AU - Zafereo, Mark

AU - Coca-Pelaz, Andrés

AU - Piazza, Cesare

AU - Dange, Prajwal

AU - Rodrigo, Juan Pablo

AU - Stenman, Göran

AU - de Keizer, Bart

AU - Nixon, Iain

AU - Sinha, Shriyash

AU - Leboulleux, Sophie

AU - Mäkitie, Antti A.

AU - Agaimy, Abbas

AU - Thompson, Lester

AU - Ferlito, Alfio

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024

Y1 - 2024

N2 - The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.

AB - The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.

KW - Artificial intelligence

KW - Bethesda system

KW - Molecular testing

KW - Risk assessment

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85186181382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85186181382&partnerID=8YFLogxK

U2 - 10.1007/s12020-024-03737-z

DO - 10.1007/s12020-024-03737-z

M3 - Review article

C2 - 38416380

AN - SCOPUS:85186181382

SN - 1355-008X

JO - Endocrine

JF - Endocrine

ER -

Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this